Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen's ... | Region

EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation within both the medical

Related Keywords

Alissa Algarin ,Eli Lilly ,Spherix Network ,Linkedin ,Dynamix ,Global Insight ,Launch Dynamix ,Global Insights ,Spherix Global Insights ,Spherix Global Insight ,Insights Director ,Neurology Spherix Global Insights ,Region ,